Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2057951 | 0.80 | NPC1 (0.43) | KDM4ERXFP1NPC1ALDH1A1EGLN1 | |
| SCHEMBL2057744 | 0.80 | EGLN1 (0.44) | EGLN1 | |
| SCHEMBL2057846 | 0.73 | EGLN1 (0.43) | EGLN1 | |
| SCHEMBL4056990 | 0.70 | EGLN1 (0.47) | EGLN1L3MBTL1EGLN3 | |
| SCHEMBL4739187 | 0.67 | EGLN3 (0.42) | EGLN1KMT2AEGLN3 | |
| SCHEMBL2058021 | 0.65 | EGLN1 (0.39) | EGLN1EGLN3 | |
| SCHEMBL3961179 | 0.65 | EGFR (0.49) | NPC1EGLN1RAB9AMEN1KMT2A | |
| SCHEMBL4058857 | 0.64 | EGLN1 (0.57) | KDM4EALDH1A1EGLN1EGLN3 | |
| SCHEMBL2385165 | 0.63 | EGLN1 (0.83) | EGLN1 | |
| SCHEMBL2582344 | 0.63 | EGLN1 (0.65) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | claimed |
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| WO-2010022307-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160227-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | KDM4E 566/4885RXFP1 2031/4885NPC1 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.